ptvg-ar
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02411786)
Timeline
Indications
Mechanism of action
- Androgen ReceptorImmunity, active
AR immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ptvg-ar
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04989946 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Department of Defense, Madison Vaccines Incorporated, University of Wisconsin |
| NCT04090528 | Phase 2 | Sep 30, 2019 | Madison Vaccines Incorporated, Merck, Prostate Cancer Foundation, University of Wisconsin |
| NCT02411786 | Phase 1 | Jul 1, 2015 | Madison Vaccines Incorporated, National Cancer Institute (NCI), University of Wisconsin |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Madison Vaccines Incorporated | For profit | 3 | 0 | 2 | 2015 |
| University of Wisconsin | Academic/Hospital | 3 | 3 | 2 | 2015 |
| Department of Defense | Government | 1 | 0 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
| Prostate Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1